.jpg)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Vical Inc (NASDAQ: VICL), with a price target of $5. The company’s shares closed on Friday at $1.57, close to its 52-week low of $1.32.
Selvaraju noted:
“Next Month; Cash Runway Solid; Reiterate Buy Stock Data 05/04/2018 Price $1.57 Exchange NASDAQ Price Target $5.00 52-Week High $3.70 52-Week Low $1.32 Enterprise Value (M) $(22.1) Market Cap (M) $34 Public Market Float (M) 14.7 Shares Outstanding (M) 21.8 3 Month Avg Volume 144,364 Short Interest (M) 0.53 Balance Sheet Metrics Cash (M) $56.1 Total Debt (M) $0.0 Total Cash/Share $2.57 Book Value/Share $2.92 EPS Diluted Full Year – Dec 2017A 2018E 2019E 1Q (0.25) (0.29)A (0.33) 2Q (0.30) (0.30) (0.35) 3Q (0.27) (0.31) (0.37) 4Q (0.22) (0.32) (0.39) FY (1.01) (1.22) (1.44) Revenue ($M) Full Year – Dec 2017A 2018E 2019E 1Q 3.2 0.7A 0.1 2Q 3.4 0.5 0.1 3Q 3.2 0.3 0.1 4Q 3.9 0.2 0.1 FY 13.8 1.7 0.4 3.5 3 2.5 2 1.5 1 MAY-17 SEP-17 JAN-18 MAY-18 8 6 4 2 0 Vol. (mil) Price 1Q18 financial results reported. Last week, Vical reported its financial results for the first quarter of 2018.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.2% and a 36.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Vical Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
Based on Vical Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.27 million. In comparison, last year the company had a GAAP net loss of $2.82 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It has active development programs which comprises of ongoing phase 2 trial of HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection; ongoing phase 2 trial of novel antifungal VL-2397, for the treatment of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
